Explore more price target data and ratings for uniQure N.V. on the Forecasts tab, and track all previous and future analyst recommendations for uniQure N.V. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a…
Regulatory submissions for AMT-130 in Huntington's disease are on track for Q3 2026, with pivotal data expected in September. Strong cash position of $810.3 million supports operations into 2030, while pipeline programs show promising early results and manageable safety profiles.Original document…
uniQure N.V. QURE now represents more than a single-program gene therapy story. Its profile is being reshaped by faster regulatory pathways, a narrower operating model and clinical work in rare neurological diseases.Those trends matter because investors are watching whether uniQure can build the ne…
uniQure N.V. QURE has surged as investors reassessed AMT-130, its lead gene therapy candidate for Huntington's disease.The question is whether the move already reflects too much optimism. Valuation, earnings quality, estimate trends and ratings point to selective caution.QURE Has Rallied Ahead of K…
uniQure N.V. QURE remains a catalyst-driven gene therapy stock, with AMT-130 shaping most of the investment debate. The program targets Huntington’s disease, an area where disease-modifying options remain absent.Recent FDA feedback, a targeted biologics license application submission in the third q…
One of the questions I get more than any other is, “Jonathan, how do you know these stocks will explode when you find them?”The honest answer is, I don’t.Nobody knows ahead of time that a stock is about to double. If someone tells you they do, I’d be skeptical. What you can do is learn to recognize…
